Role of p53 isoforms and aggregations in cancer

Area of Science:

• Molecular Biology
• Cancer Biology
• Genetics

Background:

• p53 is a key tumor suppressor protein regulating apoptosis, DNA repair, and cell cycle arrest.
• Loss of functional p53 occurs in over 50% of human cancers, impacting treatment response.
• The role of p53's diverse states and regulatory pathways in cancer remains complex and incompletely understood.

Purpose of the Study:

• To review the correlation between p53 isoforms and aggregation states with cancer pathogenesis.
• To explore how different p53 expression patterns influence normal and cancerous cell fates under stress.
• To investigate the potential impact of mutant p53 aggregation on cancer development (LoF, DN, GoF effects).

Main Methods:

• Literature review of recent studies on p53 isoforms and aggregation.
• Analysis of TP53 gene expression and alternative splicing mechanisms.
• Examination of experimental evidence linking p53 states to cancer biology.

Main Results:

• The human TP53 gene encodes at least 12 p53 isoforms generated through alternative translation, promoters, and splicing.
• Emerging evidence suggests p53 isoforms and aggregation states significantly impact normal and cancer cell behavior.
• Mutant p53 aggregation is implicated in cancer pathogenesis via loss-of-function, dominant-negative, and gain-of-function mechanisms.

Conclusions:

• p53 isoforms and aggregation states are critical determinants of cancer development and progression.
• Further research into these p53 variations is essential for improving cancer therapies and predicting clinical outcomes.
• Understanding the complex regulatory roles of p53 isoforms and aggregates offers potential therapeutic targets.